Preliminary analysis of a randomized clinical trial of adjuvant postoperative RT vs. postoperative RT plus 5-FU and levamisole in patients with TNM stage II-III resectable rectal cancer

Cafiero, Ferdinando; Gipponi, Marco; Peressini, A.; Bertoglio, Sergio; Lionetto, R.

doi:10.1002/1096-9098(200010)75:2<80::aid-jso2>3.0.co;2-o

Cited by 22 publications

(4 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Levamisole was found to be good inhibitor of tissue non-specific APase activity. This drug was also found to have anti-cancer properties; levamisole has been successfully used as an adjuvant with 5-fluorouracil in the post-surgical treatment of colorectal carcinoma (Amery, 1977;Cafiero et al, 2000).…”

Section: Discussionmentioning

confidence: 99%

Anti-proliferative effect of levamisole on human myeloma cell linesin vitro

Ramanadham

Badgu

2010

Journal of Immunotoxicology

View full text Add to dashboard Cite

Levamisole has been employed as an immunomodulatory agent in conjunction with 5-fluorouracil in the treatment of colon cancer relapse. At high doses, levamisole has been shown to have both anti-cancer and immunosuppressive activities. In vitro, levamisole has been shown to potentiate the anti-proliferative effect of 5-fluorouracil in several types of tumor cell lines; however, its mechanism of cytotoxic action and its molecular targets in cells remains to be elucidated. Here, the effect of levamisole on the proliferative response of the human multiple myeloma cell lines RPMI 8226 and U266B1 was studied in vitro. Treatment of both lines with varying concentrations of levamisole for 48 and 72 h in culture resulted in a significant inhibition of proliferation (unstimulated) in a dose-dependent manner, as assessed by an 3-[(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide dye assay. Furthermore, measurements of cell viability (using a trypan blue dye exclusion assay) clearly showed that the levamisole was cytotoxic. The preliminary evaluation of the mechanism of this cytotoxic effect revealed that this drug induced apoptosis in the myeloma cells, as evidenced by increases in the levels of DNA fragmentation, release of cytochrome c into the cytoplasm, and the activation of caspase-3 activity in the cells. The results of these studies strongly suggest that levamisole could be a potent anti-myeloma agent and might be considered in the treatment of multiple myeloma in the future.

show abstract

Section: Discussionmentioning

confidence: 99%

Anti-proliferative effect of levamisole on human myeloma cell linesin vitro

Ramanadham

Badgu

2010

Journal of Immunotoxicology

View full text Add to dashboard Cite

show abstract

“…Nuestros resultados en los tumores localizados recto son comparables a otras series, como la del Hospital 12 de Octubre 22 o la de Tepper O'Connell 20 con 1.695 casos, tanto en porcentaje libre de recidivas, como en la supervivencia global a los 5 años. Tuvimos tan sólo 5 recidivas locales (14.28%) en los casos de carcinoma de recto, por debajo del estudio de Cafiero et al 23 , en pacientes tratados con RT y el esquema de FU-Levamisol también empleado por nosotros.…”

Section: Discussionunclassified

Adenocarcinoma colorrectal: factores pronósticos de supervivencia en el tratamiento adyuvante con 5-Fluorouracilo-Levamisol (5FU-Lev)

et al. 2004

View full text Add to dashboard Cite

Resumen• Propósito: Valoración de la supervivencia global (SG) y libre de enfermedad (SLE) a 5 años y estudio de los factores pronósticos de los pacientes operados, con finalidad curativa, de adenocarcinoma colorrectal estadios II y III, que recibieron tratamiento adyuvante con 5FU-LEV.• Material y métodos: ciento veintiséis pacientes tratados con esquema 5FU-LEV durante 12 meses, entre septiembre de 1990 y noviembre de 1997.• Resultados: La SG a los 5 años es de 68.3% y la SLE de 54%. El número de ganglios afectos por el tumor y la afectación vásculo-linfática y perineural, han resultado factores pronósticos significativos tanto en la SLE como en SG a los 5 años. La existencia de obstrucción intestinal tan sólo resulta factor pronóstico significativo en la SLE a los 5 años.• Conclusiones: los resultados que presentamos son semejantes a otras grandes series conocidas, tanto en supervivencia global y libre de enfermedad como en el estudio univariante de los factores pronósticos. La afectación ganglionar continúa presentando significación pronóstica con el análi-sis multivariante.

show abstract

“…Cafiero et al . [3] randomized 218 patients with TNM stage II‐III resectable rectal cancer into adjuvant postoperative radiotherapy alone (50 Gy over 5 weeks) vs combined radiotherapy and chemotherapy with 5 FU and levamisole. The radiotherapy was completed with original or modified protocol in 170 (90%) of 189 evaluable patients in both arms.…”

Section: Colorectal Cancermentioning

confidence: 99%